Hematology and Blood Disorders

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Hematology and Blood Disorders (2024) Volume 7, Issue 4

The Impact of Genetic Mutations on Leukemia Progression and Treatment Resistance

Mark Freeman *

Department of Diagnostics and Public Health, University of Verona, Italy

*Corresponding Author:
Mark Freeman
Department of Diagnostics and Public Health, University of Verona, Italy
E-mail: mark.freeman@univr.it

Received: 2-Jan-2024, Manuscript No. aahbd-25-159337; Editor assigned: 4-Jan-2024, PreQC No. aahbd-25-159337 (PQ) Reviewed:17-Jan-2024, QC No. aahbd-25-159337Revised:24-Jan-2024, Manuscript No. aahbd-25-159337; Published:31-Jan-2024, DOI: 10.35841/aahbd-7.4.203

Citation: Freeman M. The impact of genetic mutations on leukemia progression and treatment resistance. Hematol Blood Disord. 2024;7(4):203

Visit for more related articles at Hematology and Blood Disorders

Introduction

Leukemia, a group of cancers originating in the bone marrow and blood, is characterized by the uncontrolled proliferation of abnormal white blood cells. Its classification into acute or chronic and lymphoid or myeloid types is based on the speed of disease progression and the type of blood cells affected. Genetic mutations play a critical role in leukemia's onset, progression, and response to treatment. Understanding these genetic alterations has become essential for developing targeted therapies and improving patient outcomes [1].

Genetic mutations in leukemia can occur in oncogenes, tumor suppressor genes, and genes involved in cell cycle regulation. In acute myeloid leukemia (AML), mutations in the FLT3, NPM1, and IDH1/2 genes are common and significantly impact disease progression. FLT3 mutations, particularly internal tandem duplications (ITDs), are associated with aggressive disease and poor prognosis due to their role in promoting uncontrolled cell growth. Similarly, NPM1 mutations often co-occur with other mutations and are linked to distinct clinical outcomes depending on their genetic context [2].

Chronic lymphocytic leukemia (CLL) frequently involves mutations in the TP53 gene, which encodes a key tumor suppressor protein responsible for regulating cell death and DNA repair. Loss of TP53 function leads to genomic instability and resistance to chemotherapy. Mutations in the NOTCH1 and SF3B1 genes also contribute to CLL progression by altering cell signaling and splicing mechanisms, respectively, which disrupt normal cell differentiation and survival pathways [3].

In chronic myeloid leukemia (CML), the BCR-ABL1 fusion gene resulting from a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, drives uncontrolled cell proliferation. Tyrosine kinase inhibitors (TKIs) like imatinib target the BCR-ABL1 protein and have revolutionized CML treatment. However, point mutations in the BCR-ABL1 kinase domain, such as the T315I mutation, confer resistance to first- and second-generation TKIs, necessitating the development of more potent inhibitors like ponatinib [4].

Genetic mutations not only influence leukemia progression but also play a pivotal role in treatment resistance. Resistance can be primary, where patients do not respond to initial therapy, or secondary, where resistance develops over time. In AML, FLT3-ITD mutations often lead to resistance against conventional chemotherapy and targeted inhibitors due to clonal evolution and the emergence of secondary mutations. Similarly, in CLL, TP53 mutations are a well-established predictor of poor response to chemoimmunotherapy [5].

Clonal evolution—the process by which cancer cells acquire additional mutations over time—further complicates treatment. Subclonal populations with resistance-associated mutations can expand under the selective pressure of therapy, leading to relapse. This dynamic evolution is evident in CML, where different BCR-ABL1 mutations emerge under TKI therapy, making it challenging to achieve long-term remission [6].

Advances in genomic sequencing have enabled the identification of rare and novel mutations that contribute to leukemia progression and resistance. Next-generation sequencing (NGS) allows for comprehensive profiling of the leukemia genome, facilitating personalized treatment approaches. By identifying specific mutations, clinicians can tailor therapies to target the molecular drivers of the disease, improving treatment efficacy [7].

Targeted therapies have emerged as a promising strategy to overcome genetic-driven resistance. For example, second- and third-generation FLT3 inhibitors, such as gilteritinib and quizartinib, offer effective treatment options for AML patients with FLT3 mutations. Similarly, BCL-2 inhibitors like venetoclax have shown efficacy in CLL, especially in patients with TP53 mutations, by inducing apoptosis in leukemia cells [8].

Despite these advancements, treatment resistance remains a significant challenge. Combination therapies that target multiple pathways simultaneously are being explored to prevent or overcome resistance. For instance, combining FLT3 inhibitors with BCL-2 inhibitors or chemotherapy has shown promise in AML by attacking leukemia cells through different mechanisms and limiting the survival of resistant clones [9].

Emerging therapies targeting genetic mutations also include immunotherapies like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. These treatments harness the immune system to eliminate leukemia cells, providing an alternative approach for patients with refractory or relapsed disease due to genetic resistance [10].

Conclusion

In conclusion, genetic mutations are central to the progression and treatment resistance of leukemia. Understanding the genetic landscape of leukemia has led to significant advances in targeted therapies, yet overcoming resistance remains a key challenge. Continued research into the molecular mechanisms driving leukemia and treatment resistance will be crucial for developing more effective and durable therapeutic strategies, ultimately improving patient outcomes.

References

  1. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen..Nature. 2003;40(3):395-418.

    2. Indexed at, Google Scholar, Cross Ref

  2. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia .N Engl J Med. 1999;129(2):521S-4S.

    3. Indexed at, Google Scholar

  3. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia .Nat Genet. 2003;40:395–418.

    4. Indexed at, Google Scholar, Cross Ref

  4. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers.N Engl J Med. 2017;38(1):1-22.

    5. Indexed at, Google Scholar, Cross Ref

  5. Pui CH, Hudson M, Luo X, et al. Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood .Leukemia. 2014;35(2):253-65.

    6. Indexed at, Google Scholar

  6. Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment..Semin Arthritis Rheum. 2020;24(4):398-403.

    7. Indexed at, Google Scholar, Cross Ref

  7. Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment.J Am Acad Orthop Surg. 2017;82(4):848-55.

    8. Indexed at, Google Scholar, Cross Ref

  8. Jones JP.Fat embolism and osteonecrosis.Orthop Clin North Am. 2005;28(1):65-9.

    9. Indexed at, Google Scholar, Cross Ref

  9. Goldblatt J, Sacks S, Beighton P. The orthopedic aspects of Gaucher disease.Clin Orthop Relat Res. 2021;177(5):108-91.

    10. Indexed at, Google Scholar, Cross Ref

  10. Miyanishi K, Kamo Y, Ihara H, et al. Risk factors for dysbaric osteonecrosis.Rheumat v(Oxford) 2003;20(2):64-77.

    11. Indexed at, Google Scholar, Cross Ref

Get the App